OASMIA: OASMIA PRESENTS PHASE III RESULTS FOR PACLICAL® VET IN COPENHAGEN

The company Oasmia Pharmaceutical will present the first results from a Phase
III-study with the drug candidate Paclical® Vet at a veterinary congress in
Copenhagen. The top veterinary oncologists in the USA and Europe will attend
the congress. 

Oasmia has performed a Phase III-study with the drug candidate Paclical® Vet on
dogs with mastocytoma grade II-III during 2007-2008. The company will present
the first results at the congress ESVONC and VCS joint meeting in Copenhagen
during February 28 to March 1 2008. The company is main sponsor for the
congress. 

ESVONC (European Society of Veterinary Oncology) is an association of the most
prominent veterinary oncologists in Europe. VCS (Veterinary Cancer Society) is
the ESVONC's American counterpart. The congress is the first that these two
organizations are holding together. 

- It is incredibly exciting that Oasmia has chosen to present Phase III-data at
the first world congress for cancer in animals concerning the first cytostatic
planned to be registered for veterinary use, says Annemarie T. Kristensen,
professor of oncology, Institute for Small Animal Diseases, Copenhagen
University. 

- It is very important that we can present the first Phase III-results at this
key event and we are delighted to support this congress as one of the main
sponsors, says Oasmia CEO Julian Aleksov in a comment. 

The participation and presentation will open many new collaboration
opportunities for Oasmia's veterinary medicine operations as the drug candidate
now is a lot closer to registration in Europe and the USA. 


More information is available at www.ngm.se or www.oasmia.com
For further information please contact: info@oasmia.com or call: +46 (0) 18 50
54 40 

Oasmia Pharmaceutical AB is a pharmaceutical company that specialises in the
treatment of severe diseases. 
A pharmaceutical company based on the latest concepts in bio-organic chemistry.
The main idea is to improve the treatment of serious diseases. Primarily, this
development is in oncology and treatment with cytostatics but Oasmia also
conducts research in antibiotics, asthma and neurological diseases. Oasmia has
in-house production capacity of pharmaceuticals for clinical trials, both
company related and others. Oasmia has developed several products based on
existing pharmaceuticals in a new environment, which leads to whole new
solutions for cancer treatment. These products give Oasmia a solid product
portfolio within oncology with several products in clinical or pre-clinical
phase. Oasmia is listed on NGM Eguity.